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Suprarenal graft fixation in endovascular
abdominal aortic aneurysm repair is associated
with a decrease in renal function
Athanasios Saratzis, MBBS, MRCS,a,b,c Pantelis Sarafidis, MD, PhD,d Nikolaos Melas, MD, PhD,b
James P. Hunter, MBBS, MRCS,c Nikolaos Saratzis, MD, PhD,b Dimitrios Kiskinis, PhD,b and
George D. Kitas, MD, PhD, FRCP,e Dudley, Coventry, London, and Manchester, United Kingdom; and
Thessaloniki, Greece
Introduction: Suprarenal endograft fixation is routinely used in the endovascular repair of abdominal aortic aneurysms
(EVAR) to enhance proximal endograft attachment but can be associated with an adverse outcome in renal function. This
prospective study assessed the effect of suprarenal fixation on serum creatinine concentration and estimated glomerular
filtration rate (eGFR), calculated by the Modified Diet in Renal Disease equation, 12 months after elective EVAR.
Methods: Patients undergoing elective EVAR were divided into suprarenal vs infrarenal fixation groups matched for age,
sex, smoking, and aneurysm diameter. Serum creatinine and eGFR were measured at baseline, 6, and 12 months.
Results: Included were 92 patients (twowomen) with amean age of 71 7 years, with 46 in each group. No device-related
complications were noted. Serum creatinine did not differ significantly between groups at 6 (P  .24) or 12 (P  .08)
months but significantly increased in the suprarenal group at 12 months (1.08 0.36 to 1.16 0.36 mg/dL; P< .001)
vs baseline. The eGFR (mL/min/1.73 m2) did not differ significantly at baseline between the suprarenal (85  27) and
infrarenal (80  28; P  .33) groups or at 6 months (88  29 vs 77  24, respectively; P  .07). At 12 months, the
suprarenal group had a lower eGFR (73  23) than the infrarenal group (84  26; P  .027). The eGFR at 12 months
showed a significant decrease in the suprarenal (80  28 to 73  23; P < .001) but not in the infrarenal group (85  27
to 84  26; P  .48). The drop in eGFR differed significantly at 12 months in the infrarenal vs the suprarenal (0.82 vs
6.94; P < .001) group. No patient progressed to end-stage renal disease or disclosed a drop in eGFR > 30%.
Conclusions: In contrast to previous studies, this study suggests that suprarenal endograft fixation in elective EVAR is
associated with a drop in eGFR at 12 months. (J Vasc Surg 2012;56:594-600.)
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cAbdominal aortic aneurysm (AAA) constitutes a signif-
icant health problem, present in 5% to 10% of men aged
65 years.1 Endovascular AAA repair (EVAR) is now used
in routine clinical practice, and outcomes have proven
similar or even superior to traditional open repair.2 The
proximal fixation of the stent grafts deployed in the aorta
during EVAR is of crucial importance to avoid device-
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594elated complications such as migration and endoleak.3,4
uprarenal fixation of the aortic stent grafts has been devel-
ped for the purpose of preventing stent graft migration or
ndoleak by enhancing the hemostatic seal at the proximal
ortic neck (cephalad to the aneurysm). Devices with su-
rarenal fixation, usually in the form of suprarenal bare
tents, are typically used to treat aneurysms with short or
omplicated proximal necks; midterm results are compara-
le with infrarenal fixation devices.5-8 The presence of bare
tents or barbs above the orifice of the renal arteries has led
o the assumption that the implantation of such a device
ould be associated with a decrease in renal function or
omplications such as renal artery occlusion, thrombosis, or
issection.9-12
Various studies in recent years have examined the ef-
ects of suprarenal vs infrarenal stent grant fixation during
lective EVAR on renal function, largely suggesting no
ifferences between the two practices, at least in the short-
erm. Most of these were retrospective cohort studies,13-17
ome were retrospective analyses based on prospectively
ollected data,9,18 and fewer followed a prospective cohort
esign.19,20 Most of these series had a follow-up of up to 1
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Volume 56, Number 3 Saratzis et al 595year. Some studies included creatinine clearance (based on
the Cockroft-Gault formula) instead of simple serum cre-
atinine measurements for renal function evaluation.15,19,20
However, no study so far has compared carefully balanced
groups of patients or examined renal function with the use
of the estimated glomerular filtration rate (eGFR),21 which
is currently widely used in clinical practice as the best simple
surrogate measure of renal function. The aim of the present
prospective, controlled study was to examine the 6- and
12-month effects on renal function of suprarenal vs infra-
renal proximal stent graft fixation in elective EVAR.
METHODS
Study design and population. This study followed a
predefined nested case-control design, with both cases and
controls deriving from one prospectively assembled cohort
of patients. This original cohort included patients under-
going elective EVAR of an infrarenal AAA between January
2008 and April 2010 in our tertiary referral center, who
provided written informed consent for their information to
be recorded in a prospective registry and met the inclusion
criteria of the present analysis. The primary indication for
EVAR was AAA transverse diameter 5 cm or a rapidly
increasing sac (1 cm yearly) if 5 cm; any symptomatic
infrarenal AAA was also eligible. General contraindications
for EVAR were age18 years, allergy to contrast medium,
coagulopathy, pregnancy or lactation, groin infection, life
expectancy 1 year, and connective tissue disease.
Patients were included in the present analysis if they
completed at least 1 year of follow-up and all relevant
information was available. The study excluded data for
patients with ruptured, mycotic, or inflammatory aneu-
rysms and patients with end-stage renal disease receiving
renal replacement therapy at baseline, despite eGFR levels.
The institutional Ethics Committee approved the study,
and all examinations were conducted in accordance with
the Declaration of Helsinki (2000 Amendment).
The original prospectively assembled cohort consisted
of 244 patients who fulfilled the inclusion criteria. Patients
were placed in two groups according to the mode of
proximal aortic fixation of the aortic stent graft that was
deployed in relation to the orifice of the renal arteries:
suprarenal fixation for bare suprarenal stent(s) or the infra-
renal fixation mechanism. EVAR had been done with a
device bearing suprarenal fixation in 72 patients and with-
out suprarenal fixation the device in 172 patients. To
include two balanced groups with the least selection bias,
after the original cohort was formed, one of the investiga-
tors (P.S.), blinded to patient data apart from age, sex, AAA
diameter, fixation type, and smoking history, matched pa-
tients from the suprarenal fixation group (72 cases) with
individuals from the infrarenal fixation group (172 cases)
for age (2 years), sex, AAA diameter (1 cm), and
smoking history (never, current smoker, former smoker). A
total of 46 patients from each group could be accurately
matched and represented the final population of this anal-
ysis. aStudy protocol. For each patient, demographics and
omorbidities, including a full medical and surgical history,
nd full anesthetic assessment were recorded, and a full
ascular examination was performed at baseline (before
VAR). All patients also underwent a computed tomogra-
hy angiography (CTA) with two- or three-dimensional
econstruction before repair. Blood specimens were col-
ected for a full blood count and routine biochemistry tests
efore any imaging requiring the administration of intrave-
ous contrast. All data were prospectively entered in an
lectronic database before surgery once written informed
onsent had been obtained.
All patients were followed up according to our depart-
ent’s standard EVAR protocol. This included a follow-up
isit at 30 days, 6 months, and 12 months after the opera-
ion, and annually thereafter. A clinical examination was
erformed, and routine hematology and biochemistry tests
ere obtained, all before imaging with intravenous con-
rast. Imaging included plain abdominal radiography (an-
eroposterior and lateral views) and a contrast-enhanced
TA at 6 months, 12 months, and annually thereafter.
ata from follow-up visits, including results from blood
ests, were entered in the study database.
Procedures. Indications for the deployment of a stent
raft with suprarenal fixation in this series were an infrarenal
neurysmal neck 15 mm in length or a conical-shaped
roximal aneurysmal neck.22 Patients with excessive
hrombus or calcification at the proximal aortic neck were
ot offered EVAR.
The following endovascular devices were used: Ana-
onda (Vascutek, Inchinnan, Scotland, UK), Gore Ex-
luder (W. L. Gore and Associates, Flagstaff, Ariz), End-
Fit tube graft (LeMaitre Vascular, Burlington, Mass),
ndoFit aortouniiliac device, followed by a femorofemoral
ypass (LeMaitre Vascular), Endologix Powerlink bifur-
ated device (Endologix, Irvine, Calif), Talent (Medtronic,
inneapolis, Minn), and Endurant (Medtronic). Indica-
ions and specifications for the implantation of each device
n this center have been described in detail else-
here.3,8,23,24 Whenever a bifurcated endograft could be
mplanted, the aortouniiliac configuration was avoided be-
ause it involves an extra-anatomic bypass. The team of
ascular surgeons that performed the operations selected
he devices for implant according to the anatomy of the
roximal and distal neck, the iliac configuration, and the
mount of calcification or thrombus at each landing zone.
All procedures were performed in a fully equipped
perating room with the patient under regional or general
nesthesia and fluoroscopic control, by administering io-
romide (Ultravist 300; Bayer Schering Pharma AG, Ber-
in, Germany), a nonionic contrast agent. All operations
ere performed by the same team of vascular surgeons and
nesthetists with previous experience in EVAR using all of
he devices included in the analysis.
For all patients, a standard renal protection protocol
as used before the procedure, including 1.2 g of oral
-acetylcysteine (TrebonN,Uni-Pharma, Athens, Greece)
dministered 24 hours before EVAR. Patients with a pre-
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September 2012596 Saratzis et aloperative serum eGFR 60 mL/min/1.73 m2 were
started on intravenous fluids (0.9% saline, 2 mL/kg/h) on
the day of the operation, once they were nil by mouth.
Patients with a baseline eGFR60mL/min/1.73m2were
admitted 1 day before EVAR and given intravenous normal
saline (0.9% saline, 1.5 L/24 hours) for 24 hours in addi-
tion to oral fluids until nil by mouth, when they were
commenced on 0.9% saline at 2 mL/kg/h. Urinary cathe-
terization and hourly urine output measurements were
routinely used during and after the procedure for at least 24
hours. Cardiac output monitoring was available in all cases
through a peripheral arterial line. The administration of any
contrast agent before EVAR (2 weeks) was avoided.
Nonsteroidal anti-inflammatory drugs (NSAIDs) were
stopped for at least 7 days before EVAR. Metformin was
discontinued 2 days before EVAR and was not readminis-
tered until 48 hours after the procedure. No patients re-
ceived bicarbonate infusion perioperatively.
Further, in accordance with our department’s standard
protocol for patients undergoing elective EVAR, aspirin
and clopidogrel were administered the day of the proce-
dure. Aspirin was discontinued on postoperative day 30,
and clopidogrel was continued as a lifelong treatment.25
A plain abdominal radiograph was obtained on postop-
erative day 2 to assess graft integrity and position. The
patient was usually ambulated on postoperative day 2 and
was discharged on day 3.
Study outcomes. Assessment of renal function was
based on eGFR as the primary variable of interest. eGFR
was calculated from serum creatinine measurements at reg-
ular follow-up visits with the abbreviated equation of the
Modification of Diet in Renal Disease (MDRD) study:
eGFR (mL/min/1.73 m2)  186  (serum creatinine in
mg/dL)–1.154  (age in years)–0.203  (.742 if female) 
(1.210 if black).21 All patients in the study were white
Caucasians. Serum creatinine was measured by a modified
Jaffe method in an Abbott ARCHITECT c16000 analyzer
(Abbott Diagnostics, Abbott, Park, Ill). All complications
and events during follow-up were classified and reported
according to the reporting standards for EVAR by Chaikof
et al.26
Statistical analysis. Continuous parametric data are
presented as mean value  standard deviation. Categoric
data are presented as absolute values and percentages.
Baseline differences between the two study groups for
continuous or categoric variables were evaluated with the
unpaired t-test or the Fisher exact test, respectively. For
comparisons between the baseline and the end of the study
in each study group, the paired t-test was applied. Between-
group values were compared using the unpaired t-test.
Pearson correlation was used to assess the relation between
different types of suprarenal fixation and the absolute drop
in eGFR after 1 year in the suprarenal fixation group. P 
.05 was considered statistically significant. All analyses were
performed using SPSS 17.0 software (SPSS Inc, Chicago,
Ill). AESULTS
Baseline characteristics and intraprocedural events.
he analysis included data for 92 patients (two women;
ean age, 71  7 years) who underwent EVAR of an
nfrarenal AAA with a mean transverse diameter of 6.1 
.2 cm. Baseline characteristics of the infrarenal vs suprare-
al fixation patients, which were matched in age, sex,
moking status, and AAA diameter, are summarized in
able I. The two groups did not differ significantly in
istory of hypertension, diabetes, hypercholesterolemia,
hronic obstructive pulmonary disease, myocardial infarc-
ion, congestive heart failure, peripheral arterial disease,
troke, use of statin, and use of -blockers. In addition,
oncentrations of serum urea, serum creatinine, and eGFR
ere also not statistically different between groups at base-
ine.
The anatomic characteristics of the aneurysms for both
roups are summarized in Table I. Three patients in the
uprarenal group had a conical neck (nine of 46 [6.53%]).
he mean length of the proximal neck was 13.8 0.9 mm
or the suprarenal and 16.7  1.9 mm for the infrarenal
roup (P  .001). None of these patients had a severely
ngulated proximal aneurysmal neck (45° of angulation).
The following bifurcated devices with infrarenal proxi-
al aortic support were deployed: Anaconda in 39 patients,
ndologix Powerlink in five, and Gore Excluder in two.
evices with bare stent suprarenal proximal aortic support
ncluded the Endurant bifurcated device in 22 patients,
ndoFit tubular aortic graft in 16, EndoFit aortomonoiliac
evice, followed by a femorofemoral bypass, in 6, and
alent bifurcated device in 2. Characteristics for each de-
ice are summarized in Table II.
The amount of contrast medium used during stent
raft deployment (128 36 vs 125 38mL; P .71) and
he duration of the procedure (107  19 vs 110  15
inutes; P  .38) were not significantly different between
roups (Table I). Seven of 92 patients (8%) required a
lood transfusion, all within the first 24 hours after the
rocedure: four (9%) in the infrarenal group and three (7%)
n the suprarenal group Only two patients, both in the
nfrarenal group, developed hypotension during the proce-
ure that required inotropic support. After a short stay
24 hours) in the intensive care unit, they both made an
neventful recovery.
Procedure-related events. None of the patients died
r were lost to follow-up during the 12 months. In one
atient (0.72%) in the infrarenal group, the orifice of the
eft renal artery was unintentionally covered during deploy-
ent of an Anaconda bifurcated stent graft, but this was
ecognized and the device was immediately repositioned.
he completion angiogram disclosed no further complica-
ions. Computed angiography showed no renal artery oc-
lusion, dissection, or stenosis developed during follow-up.
o patients required conversion to open repair during the
2-month period. In one patient (0.08%) in the infrarenal
roup, acute thrombosis developed in the right limb of an
naconda bifurcated stent graft, and the patient subse-
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right lower limb.
Two (2.16%) type II endoleaks occurred during
follow-up in the infrarenal fixation group. Both patients
were asymptomatic and remained under surveillance, and
no further intervention was deemed necessary. No type I
endoleaks or other device-related complications were ob-
served during the 12-month period. All patients in both
groups underwent a contrast-enhanced CTA at 6 and 12
months. Blood samples were collected before the contrast
scans. Patients with type II endoleak remained under the
same imaging protocol because they were asymptomatic
and the aneurysms did not expand.
Renal outcomes. During the 12months of follow-up,
no patients progressed to end-stage renal disease or devel-
oped acute renal failure requiring hemodialysis. Baseline
eGFR (inmL/min/1.73m2) was 85 27 (range, 32-147)
for the infrarenal group and 80  28 (range, 31-152) for
the suprarenal group (P  .33). Table III summarizes
measures of renal function at 6 and 12 months. The serum
creatinine concentration did not differ significantly be-
tween groups at 6 (P  .24) or 12 (P  .08) months after
EVAR (Table III). However, in within-group comparisons,
serum creatinine (in mg/dL) remained practically un-
changed in the infrarenal group (from 1.01  0.33 at
Table I. Characteristics of the two groups at baseline eval
Variable a Infrar
Age, years 71 
Female sex 1 (2
Smoking
Current 5 (1
Former 27 (5
AAA diameter, cm 6.1 
Comorbidities
Hypertension 38 (8
Diabetes 12 (2
Hypercholesterolemia 22 (4
COPD 3 (7
Myocardial infarction 6 (1
Congestive heart failure 1 (2
Stroke 0
Peripheral vascular disease 10 (2
Medical therapy
Statin use 30 (6
-Blocker use 12 (2
Laboratory values
Urea, mg/dL 42 
Creatinine, mg/dL 1.01 
eGFR, mL/min/1.73 m2 85 
Hemoglobin, g/dL 13.06 
WBC, 109/L 8.89 
Sodium, mEq/L 140 
Potassium, mEq/L 4.40 
Operation time, min 110 
Contrast medium, mL 125 
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary d
aData presented are mean  standard deviation for continuous variables andbaseline to 1.01  0.37 at 6 months to 1.03  0.36 at 12 oonths; P  .23) but was significantly increased in the
uprarenal group (from 1.08  0.36 at baseline to 1.10 
.36 at 6 months and 1.16  0.36 at 12 months; P 
001).
Evaluation of postoperative renal function with eGFR
in mL/min/1.73 m2) showed that there were no signifi-
ant differences between infrarenal and suprarenal fixation
t 6 months (78  24 vs 88  29; P  .075) after EVAR,
ut patients with a suprarenal device had a significantly
ower eGFR (73 23 vs 84 26; P .027) at 12 months
Table III). Again, in the infrarenal group eGFR was well
reserved during follow-up (from 85  27 at baseline to
4  26 at 12 months; P  .48) but showed a significant
rop in the suprarenal group (from 80  28 at baseline to
3  23 at 12 months; P  .001).
We also calculated eGFR change from baseline to 6 and
o 12 months for each patient. None of the patients pre-
ented a drop of eGFR of 30% at 6 or 12 months.
owever, this eGFR change differed significantly between
he groups at 6 (P .02) and 12 months (P .001; Table
II and Fig); on average, patients with infrarenal fixation
ost 0.82 mL/min/1.73 m2 (standard error [SE], 1.07),
hereas patients with suprarenal fixation lost 6.94 mL/
in/1.73 m2 (SE, 1.43). There was no correlation be-
ween the absolute drop in eGFR after 1 year and the type
n and during procedure
Type of fixation
Suprarenal P
71  7 .84
1 (2) .99
5 (11) .99
27 (59) .99
6.2  1.3 .69
40 (87) .77
9 (20) .62
27 (59) .4
1 (2) .62
1 (2) .11
4 (9) .36
4 (0) .12
14 (30) .47
35 (76) .36
17 (37) .37
44  10 .58
1.08  0.36 .31
80  28 .33
13.40  1.71 .36
8.28  2.35 .22
140  5 .13
4.54  0.59 .24
107  19 .38
128  36 .71
; eGFR, estimated glomerular filtration rate; WBC, white blood cell count.
ber (%) for categoric variables.uatio
enal
7
)
0)
9)
1.2
3)
6)
9)
)
3)
)
2)
3)
6)
16
0.33
27
1.80
2.36
4
0.56
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38f the suprarenal fixation component (P  .2, Pearson
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group) were at increased risk of developing a higher abso-
lute drop in eGFR after 1 year (P  .001, Pearson correla-
tion).
DISCUSSION
This study was designed to examine the effects of
suprarenal vs infrarenal stent graft fixation during elective
Table II. Characteristics of the endovascular devices used
Name Fabric Type of device Proximal fi
Enduranta Multi-filament
polyester
2 pieces
bifurcated
Suprarenal
length
Talenta Polyester 2 pieces
bifurcated
Suprarenal
length
Endofit
AUIb
PTFE, 2 layers 1-piece
unibody
AUI
Suprarenal
length
Endofit
tubeb
PTFE, 2 layers Tubular aortic
graft
Suprarenal
length
Endologix
Powerlinkc
PTFE Unibody
bifurcated
Infrarenal
Excluderd PTFE 2 pieces
bifurcated
Infrarenal
Anacondae Woven
polyester
3 pieces
bifurcated
Infrarenal
AUI, Aortouniiliac; PTFE, polytetrafluoroethylene; SE, self-expanding.
aMedtronic, Minneapolis, Minn.
bLeMaitre Vascular, Burlington, Mass.
cEndologix, Irvine, Calif.
dW. L. Gore and Associates, Flagstaff, Ariz.
eVascutek, Inchinnan, Scotland, UK.
Table III. Renal function outcomes and between-group
comparison during follow-up
Type of fixation
Infrarenal Suprarenal
Variable (Mean  SD) (Mean  SD) P
Creatinine, mg/dL
Baseline 1.01  0.33 1.08  0.36 .31
6 months 1.01  0.37 1.10  0.36 .24
12 months 1.03  0.36 1.16  0.36 .08
eGFR, mL/min/
1.73 m2
Baseline 85  27 80  28 .33
6 months 88  29 77  24 .07
12 months 84  26 73  23 .03
eGFR change vs
baseline
6 months 2.18  10.53 	3.19  10.81 .02
12 months 	0.82  7.30 	6.9  9.72 .001
eGFR, Estimated glomerular filtration rate; SD, standard deviation.EVAR of an AAA on renal function with a controlled tomparison. We have carefully planned to prospectively
onitor for at least 12 months all patients undergoing
VAR with infrarenal or suprarenal fixation at our tertiary
enter. When the prospective cohort was assembled, we
lindly (for outcomes) matched patients with infrarenal or
uprarenal fixation in a nested case–control design to study
wo balanced groups. We further used eGFR measure-
ents based on theMDRD formula instead of only record-
ng serum creatinine or using creatinine clearance estima-
e study
n
1st covered stent at sealing
zone
Aortic fixation hooks, barbs,
pins
m 2 SE nitinol M stents,
8-mm length, 2-mm
internal gap
Yes on the suprarenal stent,
5 pairs fixation barbs (2
mm in length)
m SE nitinol Z stent, 15  8
mm with overlapping 
20 mm
No
m Independent SE nitinol Z
stents encapsulated
within 2 layers of PTFE
No
m Independent SE nitinol Z
stents; encapsulated
within 2 layers of PTFE
No
Unibody skeleton made
from cobalt chromium
interconnected alloy
No
Independent asymmetric
nitinol Z and M stents
 15 mm
Yes on the first stent, 8
pairs of 2-mm pins
2 independent SE nitinol
fish mouth ring stents
with 8-mm gap
Yes on the second stent, 4
pairs 2-mm length
ig. Mean (standard error [SE]) changes in the estimated glomer-
lar filtration rate (eGFR) in the two groups are shown at 6 and 12
onths of follow-up.in th
xatio
15-m
15-m
17-m
17-mions.
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Volume 56, Number 3 Saratzis et al 599With this controlled and detailed evaluation, the pres-
ent study showed that suprarenal graft fixation is associated
with a decrease in renal function, with an average reduction
of7 mL/min/1.73 m2 in 12 months, whereas infrarenal
fixation was associated with an average reduction of 0.8
mL/min/1.73 m2 in the same time frame. The clear prac-
tical implication is that infrarenal fixation is not associated
with a decrease in renal function above the expected aver-
age yearly loss for this population,27,28 whereas suprarenal
fixation may be associated with up to 10% loss of renal
function at least in the first year. This means that end-stage
renal failure will quickly develop in this patient group if the
drop in renal function continues at such a rate after the first
year.
Despite this loss of renal function, no renal artery
stenosis, dissection, or occlusion was seen on any of the
CTA imaging studies during follow-up in either group. In
addition, we did not observe a significant loss of renal
function in these patients. As a result, we have to hypoth-
esize that this drop in renal function must be secondary to
other factors that cannot be picked up using conventional
CTA, such as microembolization into the renal vascula-
ture,29 during device deployment or after the procedure,
due to the existence of the suprarenal fixation modalities at
the orifice of the renal arteries. A recent study investigated
136 patients undergoing EVAR with infrarenal and su-
prarenal fixation devices to assess the rate of microembolic
events using CTAs to detect perfusion defects. Eight pa-
tients (5.9%) had bilateral microembolic cortical defects,
and interestingly, those with moderate or severe suprarenal
or infrarenal thrombus were more likely to have renal
microemboli (17% vs 0% [P .001] and 9.6% vs 1.5% [P
.08], respectively).30 The design and material (nitinol vs
stainless steel) of the suprarenal fixation component may
play a role in renal dysfunction; however, no correlation
was found in our population between the absolute drop in
eGFR after 1 year and the design of the suprarenal fixation
component (P  .2, Pearson correlation).
The findings of the present study contrast with results
of several authors who have published retrospective series
indicating that suprarenal endograft fixation does not have
a significant effect on short (12months) andmidterm (up
to 24 months) renal function,13-18 using serum creatinine
concentration or creatinine clearance (Cockroft-Gault for-
mula) as primary end points. Two previous studies that
directly compared postoperative renal function after infra-
renal and suprarenal endograft fixation, based on prospec-
tively collected data, were published by Davey et al15 and
Forbes et al31 in 2006.
Davey et al15 published a series of 92 patients under-
going EVAR with a suprarenal device compared with 87
patients undergoing EVAR with an infrarenal device. The
study was retrospective but was based on a prospective
EVAR registry. Renal function was assessed at 6, 12, and 24
months using serum creatinine and creatinine clearance.
The authors mention that paired renal data were available
for 135 patients with a minimum follow-up of 6 months;
however, the infrarenal and suprarenal groups of the study sere not matched in age, sex, smoking status, or preoper-
tive renal function. Data at 12 and 24 months were only
vailable for 46 and 38 patients with suprarenal fixation,
espectively. Differences in serum creatinine and creatinine
learance were not significant.
Forbes et al31 compared 59 patients in whom a
alent (infrarenal) endograft was deployed with 81 pa-
ients who received the Zenith device (suprarenal). The
tudy was retrospective but based on a prospective reg-
stry. Mean follow-up was 5.5 months. There was no
ifference in the reduction in creatinine clearance be-
ween the two devices.
A systematic review of the literature in 200632 identi-
ed seven retrospective studies comparing suprarenal and
nfrarenal endograft fixation. No significant difference was
ound between suprarenal and infrarenal fixation with re-
pect to renal dysfunction, but renal infarction was more
ommon in the suprarenal fixation group (combined odds
atio, 5.189; 95% confidence interval, 3.198-8.420; P 
001). A meta-analysis published in 200833 pooled data
rom four retrospective studies.13-15,18 The authors applied
ophisticated statistics to adjust for study homogeneity.
he pooled hazard ratio for deterioration of renal function
fter deploying a device with suprarenal fixation was 0.6
95% confidence interval, 0.3-10). The authors concluded
hat the available data were not sufficient to accurately
ssess the effect of suprarenal fixation.
The present study has some limitations that need to be
cknowledged. The follow-up period only extended to 12
onths; thus, as in all previous studies of the field, to what
xtent our findings are relevant to the long-term effect of
uprarenal fixation on renal function cannot be established.
Further, this study is not a randomized, controlled
linical trial randomly allocating patients to infrarenal and
uprarenal graft fixation. However, given the absence of a
andomized clinical trial in the field, we believe we provide
he best available evidence so far, as we used a careful
redefined design, including prospective recording of pa-
ient data and blind case-controlling of participants that
nded in two balanced groups.
Finally, although we only matched our patients for age,
ex, smoking status, and AAA transverse diameter, not
any studies of this type are able to control more than two
r three factors. In our case, an attempt to match for more
ariables would have led to a further significant decrease of
he study population.
ONCLUSIONS
This study suggests for the first time that suprarenal
ndograft fixation in EVAR, when compared directly with
nfrarenal fixation, is associated with a decline in renal
unction at 12 months of follow-up, in contrast to previous
ata in the field. This finding has important implications for
linical practice because it may indicate a significant draw-
ack of currently widely used aortic endografts with su-
rarenal fixation modalities. The results of this analysis
learly call for carefully designed, long-term clinical trials to
hed light on this important aspect. These devices should
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September 2012600 Saratzis et albe rather used only in patients with challenging proximal
neck anatomy that would put the fixation of the graft at
risk.
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